# ScoreItem: Potássio

**ID:** `019bf31d-2ef0-7e94-a0b6-a5a4e838d745`
**FullName:** Potássio (Exames - Laboratoriais)
**Unit:** mEq/L

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 6 artigos
- Avg Similarity: 0.603

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7e94-a0b6-a5a4e838d745`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7e94-a0b6-a5a4e838d745",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Potássio (Exames - Laboratoriais)
**Unidade:** mEq/L

**30 chunks de 6 artigos (avg similarity: 0.603)**

### Chunk 1/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.677

keplasmapotassiumasserumpotassiummaybefalselyincreased570HyperkalemiaduetodisruptioninthemechanismofshiftingpotassiumoutofcellsIncreaseinplasmaosmolarity(e.g.,dehydrationandhyperglycemia)Massivetissuebreakdown(e.g.,rhabdomyolysisandtumorlysissyndrome)b-adrenergicblockade,especiallyduringandimmediatelyafterexercise569InsulindeciencyAldosteroneblockadeNonorganicacidosisHyperkalemiaduetodisruptioninthemechanismofmovingpotassiumintocellsDisruptioninthereleaseofinsulininresponsetoraisedserumpotassium(e.g.,inuncontrolleddiabetes)Disruptiontothereleaseofaldosteroneinresponsetoaraisedserumpotassium569HyperkalemiaduetothedecreasedabilitytoexcretepotassiumAdvancingCKDresultingininabilitytoexcreteexcessivepotassiumConstipation:inadvancingCKD,thegutassumesamuchmoreimportantroleinmaintainingpotassiumbalancebyincreasingtheexcretionofpotassium571,572Medications:blockingtheRAASpathwayandothermedicationresultingintheinabilitytoexcreteexcessivepotassium(Table26)569,573Diurnalvariationinpotas

---

### Chunk 2/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.656

reserved.ªTheAuthor(s)2018.InclusionunderaCreativeCommonslicenseisprohibited.https://doi.org/10.1093/eurheartj/ehy100
chapter3www.kidney-international.orgS224KidneyInternational(2024)105(Suppl4S),S117–S314

Table25|Factorsandmechanismsthatimpactonpotassiummeasurements556,569-575Factor/mechanismPossiblecause/clinicalimplicationPseudohyperkalemia—invivoserumpotassiumisnormalandcommonlyGFRpreserved,butduringtheprocessofdrawingbloodorclotting,therehasbeenareleaseof
intracellularpotassiumTighttourniquetHand/armexercisingorclenchingatthetimeofblooddrawHemolysisduetovigorousshakingofbloodvial/inappropriateblooddrawequipment/inappropriatestorageofsamplesIfsuspected,bloodshouldberetakenandanalyzedintheappropriatemannerandtimeframe556,569Presenceofthrombocytosis/leukocytosisIfsuspected,takeplasmapotassiumasserumpotassiummaybefalselyincreased570HyperkalemiaduetodisruptioninthemechanismofshiftingpotassiumoutofcellsIncreaseinplasmaosmolarity(e.g.,dehydrationandhyperglycemia)Massivetiss

---

### Chunk 3/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.643

potassiumbalancebyincreasingtheexcretionofpotassium571,572Medications:blockingtheRAASpathwayandothermedicationresultingintheinabilitytoexcreteexcessivepotassium(Table26)569,573DiurnalvariationinpotassiumexcretionwithmostexcretioninhumansoccurringclosetonoonCircadianexcretionofkidneyelectrolyteshavebeenwelldocumented.574ClinicalrelevanceisyettobeunderstoodNotethe0.24–0.73mmol/lvariationinKþvalueswithinindividualsovera24-hourperiodPlasmavs.serumpotassiumvaluesPotassiumvaluesdifferbetweenserumandplasmavalueswithserumvaluesbeingtypicallyhigher.Healthcareprovidersneedtobeawareoftherightreference
valuesforthesample570PostprandialhyperkalemiaAskidneyfunctiondeclinesinCKD,thereisacorrespondingdeclineintheabilityofthekidneystoincreasekaliuresispostprandially,eventuallybecoming
insufcienttomaintainexternalpotassiumbalance575CKD,chronickidneydisease;GFR,glomerularltrationrate;Kþ,potassium;RAAS,renin-angiotensin-aldosteronesystem.

---

### Chunk 4/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.635

playakeyroleinpotassiumhomeostasiswithdecreasedGFR
generallyassociatedwithincreasedpotassiumconcentration
(Table24;Figure29555).Thedenitionofhyperkalemiaisbasedonthedistributionofpotassiumvaluesinthegeneral
population.HyperkalemiaisuncommonwhentheeGFRis
>60ml/minper1.73m2andincreaseswithlowerGFR.AdultswithCKDG3,A1inthegeneralandhigh-riskpop-ulationcohorts,contributingtotheCKD-PC,hadanadjusted
prevalenceofhyperkalemia(denedasaserumpotassium>5.0mmol/l)of8.8%and4.5%inthosewithandwithoutdiabetes,respectively,increasingto34.4%and23.7%byCKD
G5,A3(Figure30).541Notethatthereisvariabilityintheprevalenceofhyperkalemia,anditisnotinevitableatlower
Table24|Variationoflaboratoryvaluesinalargepopulationdatabaseabyagegroup,sex,andeGFR;potassium,mmol/l,mean(SD),andn[4,278,600Measure,mean(SD)Age(yr)SexGFRcategory(ml/minper1.73m2)105D90–10475–8960–7445–5930–4415–290–14Serumpotassium$65Female4.1(0.5)4.2(1.3)4.2(0.5)4.3(0.5)4.3(1.3)4.4(0.5)4.5(1.0)4.5(2.0)Male4.2(0.5)4.3(0.6)4.3(1.1)4.4(0.

---

### Chunk 5/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.632

223

levelsofGFR,thusunderstandingpotassiumphysiologyanditsimpactingfactorsareimportantineffectivepatientcare.HyperkalemiainpeoplewithpreservedGFRislessprev-alent.Anacuteepisodeofhyperkalemiaisapotassiumresult
abovetheupperlimitofnormalthatisnotknowntobe
chronic.Atthecurrenttime,thereisnoconsensusonthe
magnitude,duration,andfrequencyofelevatedpotassium
valuesthatdenechronicity.556InadditiontodecreasedeGFR,otherriskfactorsforhyperkalemiaincludedhigherACRandpriordiabetes,hyperglycemia,constipation,
RASi,557andMRA.536NotethatSGLT2idonotappeartoincreaseserumpotassiumvalues.403,517StudieshavedemonstratedacontinuousU-shapedrela-tionshipbetweenserumpotassiumandall-causemortality
inarangeofdifferentpopulations(Figure31).555,558Ithasalsobeenassociatedwithworsekidneyprognosis.559Observationally,theriskofdeathfromthesamedegreeof
hyperkalemiaislowerinmoreadvancedCKDstages.560–564Thismaysuggestthatthereareadaptivemechanismsthat
renderbettertolerancetoelevatedlevelsofpotassiumin
circulation.561,5

---

### Chunk 6/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** methods | **Similarity:** 0.632

alityinchronickidneydisease.AmJNephrol.2015;41:456–463.565.AllonM,ShanklinN.Effectofalbuteroltreatmentonsubsequentdialytic
potassiumremoval.AmJKidneyDis.1995;26:607–613.566.FosterES,JonesWJ,HayslettJP,etal.Roleofaldosteroneanddietarypotassiuminpotassiumadaptationinthedistalcolonoftherat.Gastroenterology.1985;88:41–46.567.GennariFJ,SegalAS.Hyperkalemia:anadaptiveresponseinchronic
renalinsufciency.KidneyInt.2002;62:1–9.568.SandleGI,GaigerE,TapsterS,etal.Evidenceforlargeintestinalcontrol
ofpotassiumhomoeostasisinuraemicpatientsundergoinglong-term
dialysis.ClinSci(Lond).1987;73:247–252.569.RastegarA.Clinicalmethods:thehistory,physical,andlaboratory
examinations.In:WalkerHK,HallWD,HurstJW,eds.SerumPotassium.3rded.Butterworth;1990:731.570.CooperLB,SavareseG,CarreroJJ,etal.Clinicalandresearchimplications
ofserumversusplasmapotassiummeasurements.EurJHeartFail.2019;21:536–537.571.MartinRS,PaneseS,VirginilloM,etal.Increasedsecretionofpotassiumintherectumofhumanswithchronicrenalfailu

---

### Chunk 7/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.626

esearchimplications
ofserumversusplasmapotassiummeasurements.EurJHeartFail.2019;21:536–537.571.MartinRS,PaneseS,VirginilloM,etal.Increasedsecretionofpotassiumintherectumofhumanswithchronicrenalfailure.AmJKidneyDis.1986;8:105–110.572.St-JulesDE,GoldfarbDS,SevickMA.Nutrientnon-equivalence:does
restrictinghigh-potassiumplantfoodshelptopreventhyperkalemiainhemodialysispatients?JRenNutr.2016;26:282–287.573.WannerC,FiorettoP,KovesdyCP,etal.Potassiummanagementwithnerenone:practicalaspects.EndocrinolDiabetesMetab.2022;5:e360.574.GumzML,RabinowitzL.Roleofcircadianrhythmsinpotassium
homeostasis.SeminNephrol.2013;33:229–236.575.St-JulesDE,CleggDJ,PalmerBF,etal.Cannovelpotassiumbindersliberatepeoplewithchronickidneydiseasefromthelow-potassiumdiet?Acautionarytale.ClinJAmSocNephrol.2022;17:467–472.576.WeinerID,LinasSL,WingoCS.Chapter10:Disordersofpotassium
metabolism.ComprehensiveClinicalNephrology.Elsevier;2024:125–136.577.Pecoits-FilhoR,FliserD,TuC,etal.Prescriptionofrenin-angiotensin

---

### Chunk 8/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.623

0.2:MonitortreatmentformetabolicacidosistoensureitdoesnotresultinserumbicarbonateconcentrationsexceedingtheupperlimitofnormalanddoesnotadverselyaffectBPcontrol,serumpotassium,oruidstatus.3.11HyperkalemiainCKD3.11.1AwarenessoffactorsimpactingonpotassiummeasurementPracticePoint3.11.1.1:Beawareofthevariabilityofpotassiumlaboratorymeasurementsaswellasfactorsandmech-anismsthatmayinuencepotassiummeasurementincludingdiurnalandseasonalvariation,plasmaversusserumsamples,andtheactionsofmedications.3.11.2Potassiumexchangeagents
PracticePoint3.11.2.1:Beawareoflocalavailabilityorformularyrestrictionswithregardtothepharmacologicman-agementofnonemergenthyperkalemia.3.11.3Timingtorecheckpotassiumafteridentifyingmoderateandseverehyperkalemiainadults[Norecommendationsandpracticepoints]
K+ ≤4.8 mmol/lK+ 4.9–5.5 mmol/lK+ >5.5 mmol/l• Initiate nerenone  - 10 mg daily if eGFR 25–59 ml/min/1.73 m2  - 20 mg daily if eGFR ≥60 ml/min/1.73 m2• Monitor K+ at 1 month after initiation and then every

---

### Chunk 9/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.623

chronickidney
disease.AmJKidneyDis.2005;46:S1–S122.555.KovesdyCP,MatsushitaK,SangY,etal.Serumpotassiumandadverse
outcomesacrosstherangeofkidneyfunction:aCKDPrognosisConsortiummeta-analysis.EurHeartJ.2018;39:1535–1542.556.ClaseCM,CarreroJJ,EllisonDH,etal.Potassiumhomeostasisandmanagementofdyskalemiainkidneydiseases:conclusionsfroma
KidneyDisease:ImprovingGlobalOutcomes(KDIGO)ControversiesConference.KidneyInt.2020;97:42–61.557.LewisEJ,HunsickerLG,ClarkeWR,etal.Renoprotectiveeffectoftheangiotensin-receptorantagonistirbesartaninpatientswith
nephropathyduetotype2diabetes.NEnglJMed.2001;345:851–860.558.CollinsAJ,PittB,ReavenN,etal.Associationofserumpotassiumwithall-causemortalityinpatientswithandwithoutheartfailure,chronic
kidneydisease,and/ordiabetes.AmJNephrol.2017;46:213–221.559.KorgaonkarS,TileaA,GillespieBW,etal.Serumpotassiumand
outcomesinCKD:insightsfromtheRRI-CKDcohortstudy.ClinJAmSocNephrol.2010;5:762–769.560.EinhornLM,ZhanM,HsuVD,etal.Thefrequencyofhyperkalemiaand
itssi

---

### Chunk 10/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.621

s206–217,Copyrightª2018,withpermissionfromtheNationalKidneyFoundation,Inc.541
00.20.40.60.81Density2.533.544.555.566.5Potassium, mmol/
eGFR 60+eGFR 30–59eGFR <30
Figure29|Distributionofbloodpotassiumingeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium,byestimatedglomerularltrationrate(eGFR).Densityreferstotheproportionofthepopulationexperiencing
serumpotassiumlevel(e.g.,0.08ofthepopulationwithaGFR>60haveapotassiumof3.8;conversely,0.2ofthepopulationwitha
GFR<30haveapotassiumof5.5).ReproducedfromKovesdyCP,MatsushitaK,SangY,etal.Serumpotassiumandadverseoutcomes
acrosstherangeofkidneyfunction:aCKDPrognosisConsortium
meta-analysis.EuropeanHeartJournal2018;39:1535–1542bypermissionofOxfordUniversityPressonbehalfoftheEuropean
SocietyofCardiology.555Allrightsreserved.ªTheAuthor(s)2018.InclusionunderaCreativeCommonslicenseisprohibited.https://doi.org/10.1093/eurheartj/ehy100
chapter3www.kidney-international.orgS224KidneyInternational(2024)105(Suppl4S),S11

---

### Chunk 11/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.613

onofbloodpotassiumingeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium,byestimatedglomerularltrationrate(eGFR)S224Figure30.Meta-analyzedadjustedprevalenceofhyperkalemia(25thand75thpercentilecohort)ingeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium,bydiabetesstatusS225Figure31.Serumpotassiumconcentrationandconfounder-adjustedriskofdeathbypresenceorabsenceofdiabetes,heartfailure(HF),orchronickidneydisease(CKD)S228Figure32.Actionstomanagehyperkalemia(potassium>5.5mmol/l)inchronickidneydiseaseS228Figure33.Potassiumabsorptionratesofplant-based,animal-based,andprocessedfoodsS229Figure34.Associationbetweenestimatedglomerularltrationrate(eGFR)andhemoglobinconcentrationfromgeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium,bydiabetesstatusS230Figure35.Associationbetweenestimatedglomerularltrationrate(eGFR)withserumconcentrationsofparathyroidhormone,phosphate,andserumcalciumingeneralpopulationand

---

### Chunk 12/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.609

gaonkarS,TileaA,GillespieBW,etal.Serumpotassiumand
outcomesinCKD:insightsfromtheRRI-CKDcohortstudy.ClinJAmSocNephrol.2010;5:762–769.560.EinhornLM,ZhanM,HsuVD,etal.Thefrequencyofhyperkalemiaand
itssignicanceinchronickidneydisease.ArchInternMed.2009;169:1156–1162.561.GaspariniA,EvansM,BaranyP,etal.Plasmapotassiumrangesassociatedwithmortalityacrossstagesofchronickidneydisease:theStockholmCREAtinineMeasurements(SCREAM)project.NephrolDialTransplant.2019;34:1534–1541.562.GoyalA,SpertusJA,GoschK,etal.Serumpotassiumlevelsandmortalityinacutemyocardialinfarction.JAMA.2012;307:157–164.563.KolasaKM.DietaryApproachestoStopHypertension(DASH)inclinicalpractice:aprimarycareexperience.ClinCardiol.1999;22:III16–III22.564.NakhoulGN,HuangH,ArrigainS,etal.Serumpotassium,end-stage
renaldiseaseandmortalityinchronickidneydisease.AmJNephrol.2015;41:456–463.565.AllonM,ShanklinN.Effectofalbuteroltreatmentonsubsequentdialytic
potassiumremoval.AmJKidneyDis.1995;26:607–613.566.FosterES,JonesWJ,Haysle

---

### Chunk 13/30
**Article:** Genética e Epigenética II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.607

de que níveis próximos a 100 causem problemas renais, apesar do receio comum.
**A deficiência de magnésio é altamente prevalente, afetando até 90% da população, e sua correção é vital, pois apenas 1% do magnésio corporal total (20-28 gramas) está no sangue, tornando os exames séricos insuficientes para avaliar o status real do mineral.**
- Estima-se que 90% da população brasileira seja carente de magnésio.
- O corpo humano contém de 20 a 28 gramas de magnésio, com 99% localizado dentro das células (ossos e tecidos), e menos de 2% no sangue, o que limita a utilidade dos exames de sangue para diagnosticar deficiência.
- A suplementação com magnésio glicina é sugerida em doses de 200 a 1.000 mg, enquanto outras formas como o malato podem fornecer cerca de 150 mg de magnésio elementar.
- A suplementação de Vitamina D deve ser acompanhada por Vitamina K2 (MK7), com doses recomendadas entre 100 e 200 microgramas.

---

### Chunk 14/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.601

riskofdeathfromthesamedegreeof
hyperkalemiaislowerinmoreadvancedCKDstages.560–564Thismaysuggestthatthereareadaptivemechanismsthat
renderbettertolerancetoelevatedlevelsofpotassiumin
circulation.561,565–5683.11.1AwarenessoffactorsimpactingonpotassiummeasurementThereareseveralfactorsandmechanismsthatmayimpactonpotassiummeasurements,includingtheactionsofmedications
thatcanincreasetheriskofdevelopinghyperkalemia.Theseare
summarizedinTables25556,569–575and26.23,576PracticePoint3.11.1.1:Beawareofthevariabilityofpo-
tassiumlaboratorymeasurementsaswellasfactorsandmechanismsthatmayinuencepotassiummeasurementincludingdiurnalandseasonalvariation,plasmaversusserumsamples,andtheactionsofmedications.TheWorkGroupwouldliketohighlightFigure26forthemonitoringofserumpotassiumduringtreatmentwitha
nonsteroidalMRA(nerenone)fromtheKDIGO2022ClinicalPracticeGuidelineforDiabetesManagementin
ChronicKidneyDisease.23HyperkalemiahasbeenassociatedwiththerapeuticactionsofeitherreducingorstoppingRASi.577–580S

---

### Chunk 15/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.595

alenceestimate.Tothereferenceestimate,themeta-analyzedoddsratiosforhyperkalemiawereappliedtoobtainprevalenceestimatesateGFR95,
80,65,35,and20ml/minper1.73m2foreachstageofalbuminuria.Theprevalenceestimateswereadjustedto60yearsold,halfmale,non-Black,20%historyofCVD,40%eversmoker,andbodymassindex30kg/m2.The25thand75thpercentilesforpredictedprevalenceweretheestimatesfromindividualcohortsinthecorrespondingpercentilesoftherandom-effectsweighteddistributionofadjustedodds.A1,
albuminuria<30mg/g(<3mg/mmol);A2,albuminuria30–300mg/g(3–30mg/mmol);A3,>300mg/g(>30mg/mmol).ReproducedfromAmericanJournalofKidneyDiseases,volume73,issue2,InkerLA,GramsME,LeveyAS,etal.RelationshipofestimatedGFRandalbuminuriatoconcurrentlaboratoryabnormalities:anindividualparticipantdatameta-analysisinaGlobalConsortium,pages206–217,Copyrightª2018,withpermissionfromtheNationalKidneyFoundation,Inc.541
00.20.40.60.81Density2.533.544.555.566.5Potassium, mmol/
eGFR 60+eGFR 30–59eGFR <30
Figure29|Distributionofbloodpotas

---

### Chunk 16/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.594

nationalLicense(CCBY-NC-ND)(http://www.karger.com/Services/OpenAccessLicense).
www.kidney-international.orgchapter3KidneyInternational(2024)105(Suppl4S),S117–S314S225

monitoring,pleaserefertoFigure21.SeeSection4.3formoreinformationoncontinuingRASiafterhyperkalemiaevents.3.11.2PotassiumexchangeagentsPracticePoint3.11.2.1:Beawareoflocalavailabilityorformularyrestrictionswithregardtothepharmacologic
managementofnonemergenthyperkalemia.Thepharmacologicmanagementofnonemergenthyper-kalemiahasanumberofclinicaltoolswiththeincreased
numberoflicensedpotassiumexchangeagents.Thesemed-
icationshavedifferingmechanismsofaction,onsetsofclin-
icaleffects,andpotentialmedicationanddisease-stateinteractions(Table27581,582).Althoughtheclassicpotassiumexchangeagentshavehadtolerabilityissues,theneweronesappeartohavefewersuchissuesandappearrelativelysafe
whenusedlongterm.575,583,584UseofthesenewerexchangeagentsmayhelpfacilitateessentialuseofRASi/MRA.

---

### Chunk 17/30
**Article:** Ritmo Circadiano Eixo HPA - Parte V (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.594

isiologia e considerações:
     - Aldosterona (zona glomerulosa): retenção de sódio e excreção de potássio; ativada por angiotensina II e parcialmente por ACTH.
     - Conceito de “baixa funcional de aldosterona” em indivíduos muito desgastados: possível excreção aumentada de sódio, fadiga, potássio elevado; confirmação por dosagem sanguínea ou salivar (saliva podendo mostrar baixa quando sangue está normal).
     - Efeito do excesso de cortisol em receptores mineralocorticoides: retenção de sódio e edema/inchaço em usuários de corticosteroides.
     - Catecolaminas: pré-formadas, liberação imediata, meia-vida de poucos minutos; efeitos agudos de cafeína/termogênicos/estresse são catecolaminérgicos; após queda das catecolaminas ocorre conversão de cortisol em cortisona, levando a necessidade de mais cafeína em pacientes fadigados com disfunção do eixo HPA.

---

### Chunk 18/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.591

oint3.11.5.2:Provideadvicetolimittheintakeoffoodsrichinbioavailablepotassium(e.g.,processedfoods)
forpeoplewithCKDG3–G5whohaveahistoryofhyperkalemiaorasapreventionstrategyduringdisease
periodsinwhichhyperkalemiariskmaybeaconcern.Dietmayincreaseserumpotassiumpostprandially,575,588butotherconditionssuchastheuseofpotassium-sparing
Table26|MedicationsassociatedwithincreasedriskofhyperkalemiaClassMechanismExampleACEiInhibitconversionofangiotensinItoangiotensinIICaptopril,lisinopril,perindopril,etc.ARBInhibitactivationofangiotensinIreceptorbyangiotensinIILosartan,irbesartan,candesartan,etc.AldosteroneantagonistBlockaldosteronereceptoractivationSpironolactone,eplerenone,andnerenoneb-AdrenergicreceptorblockerInhibitreninreleasePropranolol,metoprolol,andatenololDigitalisglycosideInhibitNaþ-Kþ-ATPase,necessaryforcollectingductKþsecretionDigoxinHeparinReducedproductionofaldosteroneHeparinsodiumPotassium-sparingdiureticBlockcollectingductapicalNaþchannel,decreasinggradientforKþsecretionAmi

---

### Chunk 19/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.590

:1002–1015.588.AllonM,DansbyL,ShanklinN.Glucosemodulationofthedisposalofan
acutepotassiumloadinpatientswithend-stagerenaldisease.AmJMed.1993;94:475–482.589.RamosCI,Gonzalez-OrtizA,Espinosa-CuevasA,etal.Doesdietary
potassiumintakeassociatewithhyperkalemiainpatientswithchronic
kidneydisease?NephrolDialTransplant.2021;36:2049–2057.590.IkizlerTA,BurrowesJD,Byham-GrayLD,etal.KDOQIclinicalpractice
guidelinefornutritioninCKD:2020update.AmJKidneyDis.2020;76:S1–S107.591.JoshiS,McMackenM,Kalantar-ZadehK.Plant-baseddietsforkidney
disease:aguideforclinicians.AmJKidneyDis.2021;77:287–296.592.PicardK,GrifthsM,MagerDR,etal.Handoutsforlow-potassiumdietsdisproportionatelyrestrictfruitsandvegetables.JRenNutr.2021;31:210–214.593.CarlisleEJ,DonnellySM,EthierJH,etal.Modulationofthesecretionof
potassiumbyaccompanyinganionsinhumans.KidneyInt.1991;39:1206–1212.594.CummingsJH,HillMJ,JenkinsDJ,etal.Changesinfecalcomposition
andcolonicfunctionduetocerealber.AmJClinNutr.1976;29:1468–1473.595.Cec

---

### Chunk 20/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.586

  472.576.WeinerID,LinasSL,WingoCS.Chapter10:Disordersofpotassium
metabolism.ComprehensiveClinicalNephrology.Elsevier;2024:125–136.577.Pecoits-FilhoR,FliserD,TuC,etal.Prescriptionofrenin-angiotensin-
aldosteronesysteminhibitors(RAASi)anditsdeterminantsinpatients
withadvancedCKDundernephrologistcare.JClinHypertens(Greenwich).2019;21:991–1001.578.BandakG,SangY,GaspariniA,etal.Hyperkalemiaafterinitiatingrenin-
angiotensinsystemblockade:theStockholmCreatinineMeasurements
(SCREAM)project.JAmHeartAssoc.2017;6:e005428.579.LazichI,BakrisGL.Predictionandmanagementofhyperkalemiaacross
thespectrumofchronickidneydisease.SeminNephrol.2014;34:333–339.580.TrevisanM,deDecoP,XuH,etal.Incidence,predictorsandclinical
managementofhyperkalaemiainnewusersofmineralocorticoid
receptorantagonists.EurJHeartFail.2018;20:1217–1226.

---

### Chunk 21/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.584

ptorantagonist.DatafromWeineretal.576andKidneyDisease:ImprovingGlobalOutcomesDiabetesWorkGroup.23
chapter3www.kidney-international.orgS226KidneyInternational(2024)105(Suppl4S),S117–S314

medications,metabolicacidosis,hyperosmosisduetohyperglycemia,hypernatremiaoruremia,andconstipation
aremorelikelytoexplainplasmapotassiumabnormalities
thandiet.545,556,572,589Althoughshort-termdietaryrestrictionofthefoodshighestinpotassiumisavalid
strategytotreatacutehyperkalemia,restrictionoffoods
highestinbioavailablepotassiummaybeasupportive
preventionstrategyforpeoplewithahistoryofhyperkalemiaorduringperiodsinwhichhyperkalemiariskisaconcern.590Increasedeffortstowardeducationonpotassiumcontentinfoodscanservetoimprovediet
qualityanddiversityformanypeoplewithCKDwherethis
Table27|Acomparisonofpotassiumexchangeagents(Polystyrenesulfonates)sodiumorcalciumPatiromerSodiumzirconiumcyclosilicate(SZC)MechanismofactionSodium-potassiumexchangeresin(SPS)orcalcium-potassiumexchangeresin(CPS)Calcium-potassiumexch

---

### Chunk 22/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.583

ssiumbyaccompanyinganionsinhumans.KidneyInt.1991;39:1206–1212.594.CummingsJH,HillMJ,JenkinsDJ,etal.Changesinfecalcomposition
andcolonicfunctionduetocerealber.AmJClinNutr.1976;29:1468–1473.595.CeccantiC,GuidiL,D’AlessandroC,etal.Potassiumbioaccessibilityinuncookedandcookedplantfoods:resultsfromastaticinvitro
digestionmethodology.Toxins(Basel).2022;14:668.596.ParpiaAS,L’AbbeM,GoldsteinM,etal.Theimpactofadditivesonthephosphorus,potassium,andsodiumcontentofcommonlyconsumed
meat,poultry,andshproductsamongpatientswithchronickidneydisease.JRenNutr.2018;28:83–90.597.PicardK,PicardC,MagerDR,etal.PotassiumcontentoftheAmericanfoodsupplyandimplicationsforthemanagementofhyperkalemiain
dialysis:ananalysisoftheBrandedProductDatabase.SeminDial.PublishedonlineJuly29,2021.https://doi.org/10.1111/sdi.13007598.ShermanRA,MehtaO.Phosphorusandpotassiumcontentofenhanced
meatandpoultryproducts:implicationsforpatientswhoreceive
dialysis.ClinJAmSocNephrol.2009;4:1370–1373.599.deAbreuDBV,PicardK,Kle

---

### Chunk 23/30
**Article:** A Comprehensive Review on Understanding Magnesium Disorders: Pathophysiology, Clinical Manifestations, and Management Strategies (2024)
**Journal:** Cureus
**Section:** abstract | **Similarity:** 0.583

Revisão abrangente de 2024 sobre distúrbios do magnésio. Fisiopatologia da hipomagnesemia decorre de ingestão dietética inadequada, perdas gastrointestinais ou excreção renal excessiva. Aproximadamente 20-30% do magnésio filtrado é reabsorvido no túbulo proximal, com taxas variáveis ao longo do néfron. Hormônios como paratormônio e vitamina D influenciam homeostase do magnésio. Manifestações clínicas: neuromusculares (cãibras, tetania); cardiovasculares (arritmias, hipertensão); metabólicas (resistência insulínica, hipocalcemia); reduz limiar convulsivo em populações suscetíveis. Estratégias de manejo: suplementação oral como terapia de primeira linha para deficiência leve-moderada (óxido ou citrato de magnésio); terapia intravenosa reservada para casos graves (1-2g de sulfato de magnésio em 15-30 minutos); tratar causas subjacentes (síndromes de má-absorção, ajustar medicações) essencial para prevenir recorrência.

---

### Chunk 24/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.579

Rcategory(ml/minper1.73m2)105D90–10475–8960–7445–5930–4415–290–14Serumpotassium$65Female4.1(0.5)4.2(1.3)4.2(0.5)4.3(0.5)4.3(1.3)4.4(0.5)4.5(1.0)4.5(2.0)Male4.2(0.5)4.3(0.6)4.3(1.1)4.4(0.6)4.4(0.7)4.5(1.1)4.6(0.6)4.6(1.6)<65Female4.1(0.7)4.2(1.3)4.3(17.0)4.2(1.0)4.3(0.5)4.3(0.6)4.4(0.6)4.5(1.1)Male4.2(0.4)4.3(0.5)4.3(0.6)4.3(0.4)4.4(0.5)4.5(0.6)4.5(0.7)4.6(0.7)eGFR,estimatedglomerularltrationrate;GFR,glomerularltrationrate.aDatafromtheOptumLabsDataWarehouse,alongitudinal,real-worlddataassetwithdeidentiedadministrativeclaimsandelectronichealthrecorddata.Thedatabasecontainslongitudinalhealthinformationonenrolleesandpatients,representingthediversityofgeographicalregionsacrosstheUnitedStates.

---

### Chunk 25/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.575

maintainexternalpotassiumbalance575CKD,chronickidneydisease;GFR,glomerularltrationrate;Kþ,potassium;RAAS,renin-angiotensin-aldosteronesystem.
8.07.57.06.56.05.55.04.54.03.53.02.5Baseline serum potassium level, mEq/l00.10.20.30.40.50.60.70.80.91.0Predicted probability of mortalityHF, CKD, and DMCKDHFDMControl group
Figure31|Serumpotassiumconcentrationandconfounder-adjustedriskofdeathbythepresenceorabsenceofdiabetes,heartfailure(HF),orchronickidneydisease(CKD).ReproducedfromCollinsAJ,PittB,ReavenN,etal.Associationofserumpotassiumwithall-causemortalityinpatientswithandwithoutheartfailure,chronickidneydisease,and/ordiabetes.AmJNephrol.2017;46:213–221.558ª2017TheAuthor(s)PublishedbyS.KargerAG,Basel.ThisarticleislicensedundertheCreativeCommonsAttribution-NonCommercial-NoDerivatives
4.0InternationalLicense(CCBY-NC-ND)(http://www.karger.com/Services/OpenAccessLicense).

---

### Chunk 26/30
**Article:** Dieta Cetogênica - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.574

sa magra.
**Operacionalização e fisiologia: hidratação, eletrólitos, glicose, glicogênio e métricas (GKI) reduzem sintomas iniciais e orientam terapia.**
- Fase inicial: mobilização de ~500 g de glicogênio (100 g fígado, 400 g músculo) libera ~1 kg de água (2 g água por 1 g glicogênio), explicando “perda de água” na primeira semana.
- Hidratação/eletrólitos: ~2 litros de líquidos/dia; 1 colher de chá de sal seguida de água melhora sintomas em ~15 minutos; considerar sensibilidade ao sal (10%–20% dos hipertensos podem piorar).
- Glicemia: dieta normal 80–120 mg/dL; cetogênica 65–80 mg/dL; jejum em gestantes ~60 mg/dL; <70 mg/dL pode ser perigoso com insulina; extremos incluem 600 mg/dL em DT1 sem insulina e >300 mg/dL na cetoacidose; em jejum prolongado, 30 mg/dL pode ser tolerado quando há cetonas.

---

### Chunk 27/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.572

tagechronickidneydisease:comparativeresultsfromanopen-label,phase3study.NephrolDialTransplant.2021;36:137–150.585.ThinkKidneys,theRenalAssociationandtheBritishSocietyforHeartFailure.ChangesinkidneyfunctionandserumpotassiumduringACE/
ARB/diuretictreatmentinprimarycare.Apositionstatement;2017.

---

### Chunk 28/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.569

rgS160KidneyInternational(2024)105(Suppl4S),S117–S314

3.11.4Managinghyperkalemia[Norecommendationsandpracticepoints]3.11.5DietaryconsiderationsPracticePoint3.11.5.1:ImplementanindividualizedapproachinpeoplewithCKDG3–G5andemergenthyperkalemiathatincludesdietaryandpharmacologicinterventionsandtakesintoconsiderationassociatedcomor-biditiesandqualityoflife(QoL).Assessmentandeducationthrougharenaldietitianoranaccredited
nutritionproviderareadvised.PracticePoint3.11.5.2:Provideadvicetolimittheintakeoffoodsrichinbioavailablepotassium(e.g.,processedfoods)forpeoplewithCKDG3–G5whohaveahistoryofhyperkalemiaorasapreventionstrategyduringdiseaseperiodsinwhichhyperkalemiariskmaybeaconcern.3.12Anemia
TheKDIGO2012ClinicalPracticeGuidelineforAnemiainChronicKidneyDiseasewillbeupdatedin2024.4373.13CKD-MineralBoneDisorder(CKD-MBD)
TheWorkGrouphighlightstheKDIGO2017ClinicalPracticeGuidelineUpdatefortheDiagnosis,Evaluation,Prevention,andTreatmentofChronicKidneyDisease–MineralandBoneDisorder(CKD-MBD)

---

### Chunk 29/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.569

arrhea,and
constipation)Insufcientpostmarketingsurveillanceatpresenttoevaluatelong-term/
rareeventsGI,gastrointestinal.ModiedfromBridgemanMB,ShahM,FooteE.Potassium-loweringagentsforthetreatmentofnonemergenthyperkalemia:pharmacology,dosingandcomparativeefcacy.NephrologyDialysisTransplantation,Volume34,Supplement3,pagesiii45–iii50.581ªTheAuthor(s)2019.PublishedbyOxfordUniversityPressonbehalfofERA-EDTA.Allrightsreserved.

---

### Chunk 30/30
**Article:** Mitocôndrias - Parte VI (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.563

etinol, ampliar por que medidas séricas podem não refletir o status corporal total (ex: distribuição tecidual, homeostase, marcadores funcionais) aprofundaria o raciocínio clínico.
### 3. Magnésio e Ácido Alfa-Lipoico
- **Magnésio:** Um terço do magnésio celular está na mitocôndria, complexado com ATP; cofator da cadeia de transporte de elétrons. Medição sanguínea é dispensável segundo o instrutor. Níveis ideais, por estudos, >2,1, pois a deficiência funcional precede a hipomagnesemia sérica.
- **Ácido Alfa-Lipoico (ALA):** Cofator de enzimas mitocondriais críticas; antioxidante amplamente estudado, atuante em meios hidrossolúveis e lipossolúveis.
> **Sugestões da IA**
> A distinção entre referência laboratorial e “intervalo de saúde” para magnésio é crucial e bem colocada. Ao introduzir ALA como antioxidante chave, antecipe uma ou duas aplicações clínicas (ex: neuropatia diabética) para criar um gancho para a discussão futura.
### 4.

---

